The ancient weapon seems to be a rare type of iron sword made in the Frankish Empire. While clearing a field on his farm, a ...

Viking Therapeutics is pulling up some extra long boats full of reasons the metabolic dysfunction-associated steatohepatitis (MASH) drug VK2809 could be a winner, but executives were mum on exactly ...

Viking Therapeutics stock crumbled Tuesday despite seemingly positive test results for a drug that treats a serious liver disease.Please watch the video at Investors.com - Glitches, Elections And ...

Viking Therapeutics (VKTX) stock fell after a conference call discussing data from a successful mid-stage trial for its liver disease therapy VK2809. Read more here.

The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.

Weight loss drug developer Viking Therapeutics (NASDAQ:VKTX) traded higher premarket Tuesday after announcing 52-week data from a mid-stage trial for VK2809 targeted at the liver disorder ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on June 2. Joseph Pantginis ...

River cruise operator Viking reported first-quarter results on Wednesday morning. The stock sank on the news. Viking's ...

Viking Holdings Ltd (NYSE:VIK) traded lower in early action on Wednesday after the cruise line operator issued its first ...

Viking starts third season in the Great Lakes, with both of its identical expedition ships, the Viking Octantis and ...

Viking Masek Packaging Technologies announced this week that two company leaders have transitioned into passive investors.